Jacques Mizrahi spent the past 25 years in drug discovery and translational medicine in several pharmaceutical companies including GSK, Eli Lilly and Roche. At Roche (Basel, Switzerland), he directed the Global Therapy Area of Metabolic and Cardiovascular Diseases and before that has been in charge of the
Clinical Research and Exploratory Medicine in the same area.
Jacques is a board member of Aelis Farma (Bordeaux, France), Elsalys Biotech (Strasbourg, France) and is a founder of Inception IBD. He has been appointed recently as Chairman of the Scientific advisory commitee of Inserm Transfer Initiative (ITI).
Jacques was trained at the Physiology-Pharmacology department of the University of Sherbrooke-medical school (Canada) and completed his Post-doctoral studies at Inserm in the department of vascular pathology and renal endocrinology (Inserm unit 36).